Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. It offers cell and gene therapy, clinical pharmacology, complex biologics, decision analytics and modeling, drug development and regulatory strategy, and model-based analysis services. The company was founded on June 27, 2017, and is headquartered in Radnor, PA.
Current Value
$9.901 Year Return
Current Value
$9.901 Year Return
Market Cap
$1.59B
P/E Ratio
-50.82
1Y Stock Return
-31.48%
1Y Revenue Growth
5.62%
Dividend Yield
0.00%
Price to Book
1.5
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CRL | 52.52% | $9.52B | -3.20% | 0.00% |
VVV | 46.78% | $4.98B | +11.54% | 0.00% |
SDGR | 46.09% | $1.38B | -35.46% | 0.00% |
NTLA | 45.26% | $1.44B | -50.35% | 0.00% |
IQV | 44.95% | $34.73B | -7.77% | 0.00% |
VPG | 44.08% | $279.20M | -30.23% | 0.00% |
EYE | 43.43% | $888.30M | -42.18% | 0.00% |
PHR | 43.41% | $1.07B | +20.61% | 0.00% |
ABCL | 42.80% | $800.44M | -37.56% | 0.00% |
RDNT | 42.76% | $5.91B | +151.89% | 0.00% |
AZTA | 42.56% | $2.00B | -28.24% | 0.00% |
KN | 42.48% | $1.60B | +12.19% | 0.00% |
SAFE | 41.82% | $1.47B | +9.32% | 3.47% |
NVST | 41.76% | $3.49B | -15.41% | 0.00% |
CWH | 41.35% | $1.36B | +5.90% | 2.22% |
FOR | 41.29% | $1.48B | -8.19% | 0.00% |
SIG | 41.19% | $4.17B | +17.93% | 1.17% |
DDD | 40.99% | $402.06M | -35.13% | 0.00% |
AMWD | 40.87% | $1.46B | +29.41% | 0.00% |
CTS | 40.74% | $1.58B | +33.53% | 0.30% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
VIRT | 0.09% | $3.17B | +110.38% | 2.60% |
BMA | 0.13% | $5.08B | +232.03% | 6.53% |
BSM | -0.13% | $3.17B | -13.01% | 10.65% |
UNM | -0.14% | $13.16B | +69.20% | 2.16% |
RSG | 0.16% | $66.05B | +31.79% | 1.04% |
VOD | -0.16% | $23.21B | -4.39% | 10.89% |
GGAL | 0.17% | $6.81B | +291.69% | 0.50% |
TPL | 0.20% | $32.63B | +163.13% | 0.64% |
REYN | -0.22% | $5.79B | +3.76% | 3.35% |
LFVN | -0.25% | $169.84M | +130.61% | 1.10% |
WM | 0.40% | $87.92B | +27.58% | 1.34% |
GSK | 0.46% | $68.24B | -5.43% | 4.71% |
TPST | -0.51% | $37.75M | -77.59% | 0.00% |
K | -0.55% | $27.77B | +52.50% | 2.79% |
PAM | 0.56% | $4.32B | +86.28% | 0.00% |
CRCT | -0.61% | $1.12B | -19.90% | 1.91% |
CEG | -0.61% | $73.37B | +91.48% | 0.59% |
TH | -0.63% | $839.02M | -24.49% | 0.00% |
TW | -0.65% | $28.66B | +42.39% | 0.29% |
CEPU | 0.71% | $2.07B | +87.28% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PGR | -13.65% | $149.10B | +57.29% | 0.45% |
COR | -10.93% | $47.48B | +21.20% | 0.86% |
MCK | -10.44% | $78.15B | +35.51% | 0.42% |
FTNT | -10.21% | $69.59B | +72.67% | 0.00% |
LRN | -10.12% | $4.43B | +74.97% | 0.00% |
XGN | -9.78% | $62.26M | +127.74% | 0.00% |
RNR | -9.15% | $13.74B | +23.09% | 0.58% |
CBOE | -8.95% | $21.46B | +15.84% | 1.11% |
HUSA | -8.91% | $16.69M | -11.56% | 0.00% |
CYD | -8.89% | $364.46M | -2.94% | 4.26% |
ACGL | -7.83% | $36.00B | +16.84% | 0.00% |
CMTL | -7.24% | $84.44M | -76.16% | 0.00% |
AJG | -7.22% | $64.17B | +17.51% | 0.80% |
MRK | -6.89% | $244.21B | -5.55% | 3.18% |
MVO | -6.43% | $106.15M | -22.78% | 16.78% |
PG | -6.15% | $402.15B | +14.14% | 2.33% |
ORLY | -5.81% | $69.31B | +22.06% | 0.00% |
BTCT | -5.15% | $42.61M | +353.33% | 0.00% |
LITB | -5.03% | $35.48M | -75.45% | 0.00% |
CAH | -4.95% | $28.64B | +12.14% | 1.70% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
DFSV | 49.92% | $4.16B | 0.31% |
NUSC | 49.91% | $1.27B | 0.31% |
DFAT | 49.75% | $11.16B | 0.28% |
EZM | 49.69% | $823.84M | 0.38% |
RSPA | 49.58% | $273.87M | 0% |
PRFZ | 49.39% | $2.65B | 0.39% |
GNOM | 49.34% | $70.59M | 0.5% |
ESML | 49.23% | $1.90B | 0.17% |
CALF | 49.18% | $8.93B | 0.59% |
IBB | 49.14% | $6.66B | 0.45% |
KOMP | 49.10% | $2.09B | 0.2% |
GSSC | 49.08% | $529.86M | 0.2% |
VTWO | 49.05% | $12.38B | 0.1% |
XHE | 49.05% | $213.41M | 0.35% |
IJT | 48.98% | $6.64B | 0.18% |
IWO | 48.92% | $12.56B | 0.24% |
IWM | 48.85% | $75.73B | 0.19% |
SPSM | 48.78% | $12.72B | 0.03% |
IJR | 48.69% | $90.05B | 0.06% |
IWC | 48.62% | $933.99M | 0.6% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IBHD | -0.07% | $327.80M | 0.35% |
COMT | -0.45% | $829.06M | 0.48% |
GSG | 0.83% | $914.42M | 0.75% |
WEAT | -0.94% | $120.27M | 0.28% |
PDBC | 1.05% | $4.40B | 0.59% |
FMF | 1.13% | $244.61M | 0.95% |
BCI | 1.26% | $1.20B | 0.26% |
DBC | 1.35% | $1.39B | 0.87% |
CORN | -1.75% | $61.12M | 0.2% |
DBMF | 1.98% | $1.02B | 0.85% |
HDRO | 2.10% | $164.26M | 0.3% |
USCI | -2.46% | $185.47M | 1.07% |
IVOL | 2.48% | $548.70M | 1.02% |
TPMN | 2.50% | $40.60M | 0.65% |
FTGC | 2.53% | $2.17B | 1.02% |
DBO | -2.60% | $217.57M | 0.77% |
SOYB | 2.73% | $27.32M | 0.22% |
SEIX | 2.75% | $268.81M | 0.62% |
ULST | -3.25% | $535.47M | 0.2% |
BCD | 3.26% | $245.02M | 0.3% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -41.60% | $388.04M | 1.43% |
USDU | -23.17% | $201.97M | 0.5% |
EQLS | -22.99% | $76.08M | 1% |
VIXY | -18.65% | $195.31M | 0.85% |
UUP | -17.30% | $309.25M | 0.77% |
TAIL | -14.91% | $67.98M | 0.59% |
AGZD | -9.82% | $142.76M | 0.23% |
KMLM | -8.48% | $353.87M | 0.9% |
CTA | -8.04% | $350.27M | 0.78% |
UNG | -7.40% | $908.80M | 1.06% |
CANE | -7.36% | $17.72M | 0.29% |
KCCA | -6.88% | $220.51M | 0.87% |
JUCY | -6.86% | $324.29M | 0.6% |
CLOI | -5.44% | $715.40M | 0.4% |
DBE | -3.75% | $50.13M | 0.77% |
DBA | -3.74% | $755.88M | 0.93% |
HIGH | -3.73% | $302.78M | 0.51% |
ULST | -3.25% | $535.47M | 0.2% |
DBO | -2.60% | $217.57M | 0.77% |
USCI | -2.46% | $185.47M | 1.07% |
Yahoo
The London Company, an investment management company, released “The London Company Small Cap Strategy” third quarter 2024 investor letter. A copy of the letter can be downloaded here. In the quarter, the fund appreciated 7.1% (7%, net) compared to a 9.3% increase in the Russell 2000 Index. The positive impact of sector allocation was mitigated […]
Yahoo
Q3 2024 Certara Inc Earnings Call
Yahoo
Certara Inc (CERT) reports an 11% revenue increase and strategic expansion, despite challenges in regulatory services.
Yahoo
Certara (CERT) delivered earnings and revenue surprises of 18.18% and 0.92%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
Updates Full Year 2024 Financial GuidanceRADNOR, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2024. Third Quarter Highlights: Revenue was $94.8 million, compared to $85.6 million in the third quarter of 2023, representing growth of 11%. Software revenue was $35.9 million, compared to $31.3 million in the third quarter of 2023, representing growth o
SeekingAlpha
Certara, Inc. (NASDAQ:CERT) Q3 2024 Earnings Conference Call November 6, 2024 5:00 PM ETCompany ParticipantsDavid Deuchler - IR, Gilmartin Group LLCWilliam...
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.